IL231825A0 - Formulations of ethenecept stabilized with metal ions - Google Patents

Formulations of ethenecept stabilized with metal ions

Info

Publication number
IL231825A0
IL231825A0 IL231825A IL23182514A IL231825A0 IL 231825 A0 IL231825 A0 IL 231825A0 IL 231825 A IL231825 A IL 231825A IL 23182514 A IL23182514 A IL 23182514A IL 231825 A0 IL231825 A0 IL 231825A0
Authority
IL
Israel
Prior art keywords
metal ions
etanercept formulations
formulations stabilized
stabilized
etanercept
Prior art date
Application number
IL231825A
Other languages
English (en)
Hebrew (he)
Original Assignee
Coherus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coherus Biosciences Inc filed Critical Coherus Biosciences Inc
Publication of IL231825A0 publication Critical patent/IL231825A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
IL231825A 2011-10-18 2014-03-31 Formulations of ethenecept stabilized with metal ions IL231825A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161548518P 2011-10-18 2011-10-18
US201261669480P 2012-07-09 2012-07-09
PCT/US2012/060739 WO2013059406A1 (en) 2011-10-18 2012-10-18 Etanercept formulations stabilized with metal ions

Publications (1)

Publication Number Publication Date
IL231825A0 true IL231825A0 (en) 2014-05-28

Family

ID=48136153

Family Applications (6)

Application Number Title Priority Date Filing Date
IL231825A IL231825A0 (en) 2011-10-18 2014-03-31 Formulations of ethenecept stabilized with metal ions
IL231827A IL231827A0 (en) 2011-10-18 2014-03-31 Formulations of etanercept stabilized with meglumine
IL231826A IL231826A0 (en) 2011-10-18 2014-03-31 Formulations of ethenecept stabilized with sodium chloride
IL231829A IL231829A0 (en) 2011-10-18 2014-03-31 Formulations of etanercept stabilized with additions of sugars and polyols
IL231828A IL231828A0 (en) 2011-10-18 2014-03-31 Formulations of ethenecept stabilized with xylitol
IL231824A IL231824A0 (en) 2011-10-18 2014-03-31 Formulations of etanercept stabilized with amino acids

Family Applications After (5)

Application Number Title Priority Date Filing Date
IL231827A IL231827A0 (en) 2011-10-18 2014-03-31 Formulations of etanercept stabilized with meglumine
IL231826A IL231826A0 (en) 2011-10-18 2014-03-31 Formulations of ethenecept stabilized with sodium chloride
IL231829A IL231829A0 (en) 2011-10-18 2014-03-31 Formulations of etanercept stabilized with additions of sugars and polyols
IL231828A IL231828A0 (en) 2011-10-18 2014-03-31 Formulations of ethenecept stabilized with xylitol
IL231824A IL231824A0 (en) 2011-10-18 2014-03-31 Formulations of etanercept stabilized with amino acids

Country Status (28)

Country Link
US (21) US9393305B2 (enExample)
EP (6) EP2768535A4 (enExample)
JP (6) JP6220789B2 (enExample)
KR (7) KR20140079491A (enExample)
CN (6) CN104010654B (enExample)
AR (6) AR088382A1 (enExample)
AU (6) AU2012326080B2 (enExample)
BR (6) BR112014009131A8 (enExample)
CA (6) CA2851651A1 (enExample)
CY (1) CY1121843T1 (enExample)
DK (1) DK2768525T3 (enExample)
EA (6) EA201490804A1 (enExample)
ES (1) ES2734070T3 (enExample)
HK (3) HK1200722A1 (enExample)
HR (1) HRP20191215T1 (enExample)
HU (1) HUE045624T2 (enExample)
IL (6) IL231825A0 (enExample)
IN (3) IN2014CN02592A (enExample)
LT (1) LT2768525T (enExample)
MX (7) MX367054B (enExample)
PL (1) PL2768525T3 (enExample)
PT (1) PT2768525T (enExample)
RS (1) RS59179B1 (enExample)
SG (6) SG11201401562RA (enExample)
SI (1) SI2768525T1 (enExample)
SM (1) SMT201900422T1 (enExample)
TW (6) TWI595883B (enExample)
WO (6) WO2013059410A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3351269B1 (en) 2005-06-14 2020-01-29 Amgen Inc. Self-buffering protein formulations
US10485869B2 (en) 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
CN104010654B (zh) * 2011-10-18 2017-10-27 科荣生生物科学公司 金属离子稳定的依那西普制剂
HK1209343A1 (en) * 2012-07-09 2016-04-01 Coherus Biosciences, Inc. Etanercept formulations exhibiting marked reduction in sub-visible particles
HRP20180182T1 (hr) 2012-09-11 2018-04-20 Coherus Biosciences, Inc. Pravilno presavijeni etanercept visoke čistoće i izvanrednog prinosa
JP2016518386A (ja) * 2013-05-02 2016-06-23 マブキシェンス エス．アー． ＴＮＦＲ：Ｆｃ融合ポリペプチドの代替配合物
WO2015056613A1 (ja) * 2013-10-15 2015-04-23 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 安定化されたポリペプチド水性製剤
SG10201803178UA (en) * 2013-10-24 2018-05-30 Astrazeneca Ab Stable, aqueous antibody formulations
JP6798882B2 (ja) * 2013-11-29 2020-12-09 アレス トレーディング ソシエテ アノニム ＴＮＦＲ及びＦｃ領域を含む融合タンパク質の液体製剤
IS3008B (is) * 2014-05-14 2018-12-15 Calor ehf Stöðgandi lausnir fyrir prótín og peptíð
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
US20160074515A1 (en) 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
JP6781508B2 (ja) * 2014-11-18 2020-11-04 塩野義製薬株式会社 安定化されたペプチド組成物
HK1244685A1 (zh) * 2014-12-22 2018-08-17 阿雷斯贸易股份有限公司 液体药物组合物
EP3236942A1 (en) * 2014-12-23 2017-11-01 Drug Discovery Laboratory AS Protein compositions and use thereof
MX394035B (es) * 2014-12-31 2025-03-21 Lg Chemical Ltd Procedimiento para preparar una proteina de fusion tnfr-fc que contiene un contenido objetivo de impurezas.
CN104694355B (zh) * 2015-03-20 2016-09-28 吉林大学 葛根护肝保健酒及其制备方法
MX389818B (es) * 2015-08-13 2025-03-20 Landsteiner Scient S A De C V Composicion de estabilidad mejorada de etanercept.
JP5938762B1 (ja) * 2015-09-01 2016-06-22 日揮株式会社 マイクロカプセル製剤及びその製造方法
CN105748414A (zh) * 2016-03-02 2016-07-13 张光泉 抗感染米卡芬净冻干组合物及其制备方法
WO2017179683A1 (ja) * 2016-04-15 2017-10-19 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 ミカファンギンの安定化された医薬組成物
JP6884858B2 (ja) * 2016-10-21 2021-06-09 アムジエン・インコーポレーテツド 医薬製剤及びその製造方法
EP3533441A4 (en) * 2016-10-28 2019-12-04 Celltrion Inc. STABLE PHARMACEUTICAL FORMULATION
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
MX2017013995A (es) * 2017-10-31 2019-05-01 Probiomed S A De C V Formulacion farmaceutica estable de una proteina de fusion.
RU2020121415A (ru) * 2017-11-30 2021-12-30 Био-Тера Солюшнз, Лтд. Жидкий препарат гуманизированного антитела для лечения заболеваний, опосредованных ил-6
KR102494021B1 (ko) * 2017-12-22 2023-02-06 삼성바이오에피스 주식회사 Vegf 길항제를 포함하는 액상 조성물
US11253569B2 (en) 2018-05-03 2022-02-22 Seattle Children's Hospital Methods of treating Kawasaki Disease
CN111228225B (zh) * 2018-11-28 2022-08-26 鲁南制药集团股份有限公司 一种重组人肿瘤坏死因子受体-Fc融合蛋白冻干制剂
GB201911461D0 (en) 2019-08-09 2019-09-25 Arecor Ltd Novel composition
CA3159377A1 (en) * 2019-11-26 2021-06-03 David S. Soane Excipient compounds for biopolymer formulations
KR20230146579A (ko) 2021-02-17 2023-10-19 아레콜 리미티드 Fc 도메인을 포함하는 조작된 단백질 작제물의 수성 조성물
CN114788809B (zh) * 2022-01-25 2023-04-14 江苏广承药业有限公司 一种氯雷他定液体制剂

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
NZ256293A (en) 1992-09-15 1997-06-24 Immunex Corp Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist
US5580856A (en) 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US5656730A (en) 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
US6677326B2 (en) * 1999-03-15 2004-01-13 Arakis, Ltd. Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
EP1171148A2 (en) 1999-04-19 2002-01-16 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical desorders
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
EP1261364A1 (en) 2000-02-10 2002-12-04 Wyeth Method of treating or inhibiting cellular injury or cell death
PT1314437E (pt) 2000-08-11 2014-08-29 Chugai Pharmaceutical Co Ltd Preparações estabilizadas contendo anticorpo
US6936437B2 (en) * 2001-02-23 2005-08-30 Lucia Irene Gonzalez-Villasenor Methods and compositions for production of recombinant peptides
PT1946776T (pt) * 2002-02-27 2017-03-17 Immunex Corp Composição de tnfr-fc estabilizada compreendendo arginina
PL213501B1 (pl) * 2003-02-28 2013-03-29 Ares Trading Sa Wodny preparat bialka wiazacego czynnik martwicy nowotworu i sposób jego wytwarzania
WO2004082715A1 (ja) 2003-03-20 2004-09-30 Eisai Co., Ltd. 炎症性腸疾患治療剤としての併用医薬
JP2007521315A (ja) 2003-08-01 2007-08-02 アムジェン インコーポレイテッド 結晶性腫瘍壊死因子レセプター２ポリペプチド
RS20060259A (sr) 2003-10-14 2008-08-07 Intermune Inc., Makrociklične karboksilne kiseline i acilsulfonamidi kao inhibitori replikacije hcv
WO2005082377A1 (ja) * 2004-03-01 2005-09-09 Ajinomoto Co., Inc. 抗ヒトTNF-α抗体活性低下抑制剤
EP1720972B1 (en) 2004-03-05 2014-01-08 DSM IP Assets B.V. Process for cell culturing by continuous perfusion and alternating tangential flow
US20070196364A1 (en) 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
US7597884B2 (en) * 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
WO2006122187A2 (en) 2005-05-10 2006-11-16 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
EP1908482B1 (en) 2005-06-10 2017-09-06 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
EP3351269B1 (en) * 2005-06-14 2020-01-29 Amgen Inc. Self-buffering protein formulations
PL1962886T6 (pl) * 2005-12-20 2023-03-13 Bristol-Myers Squibb Company Stabilne formulacje białkowe
JP5405122B2 (ja) 2005-12-21 2014-02-05 ワイス・エルエルシー 低粘度のタンパク質製剤およびその用途
US20080071063A1 (en) 2006-02-03 2008-03-20 Medimmune, Inc. Protein Formulations
CA2646508A1 (en) 2006-03-17 2007-09-27 Biogen Idec Ma Inc. Stabilized polypeptide compositions
EP1996076A2 (en) 2006-03-21 2008-12-03 Eugen Oetringer Devices for and methods of analyzing a physiological condition of a physiological subject based on a workload related property
US20080003220A1 (en) 2006-04-21 2008-01-03 Amgen, Inc. Buffering agents for biopharmaceutical formulations
CN103540575A (zh) * 2006-08-01 2014-01-29 奇尼塔二有限责任公司 医药制造方法
JP5631591B2 (ja) 2006-10-06 2014-11-26 アムジエン・インコーポレーテツド 安定な抗体製剤
MX2009003982A (es) 2006-10-20 2009-04-27 Amgen Inc Formulaciones de polipeptido estables.
MX2009004519A (es) 2006-11-03 2009-05-12 Wyeth Corp Sustancias que inhiben la glucolisis en un cultivo de celulas.
ES2748526T3 (es) 2006-12-21 2020-03-17 Amgen Inc Formulaciones tamponadas estables que contienen polipéptidos
EP2924113B1 (en) 2007-03-02 2019-04-10 Wyeth LLC Use of copper and glutamate in cell culture for production of polypeptides
EP2014760A1 (en) 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process
JP2010529999A (ja) 2007-06-14 2010-09-02 バイオジェン・アイデック・エムエイ・インコーポレイテッド 抗体製剤
CN101969971A (zh) * 2007-11-30 2011-02-09 雅培制药有限公司 蛋白制剂及其制备方法
RU2537139C2 (ru) * 2008-01-15 2014-12-27 Эбботт Гмбх Унд Ко.Кг Порошковые белковые композиции и способы их получения
AU2009222115A1 (en) 2008-02-29 2009-09-11 Biogen Idec Ma Inc. Purified immunoglobulin fusion proteins and methods of their purification
WO2011015926A1 (en) 2009-08-03 2011-02-10 Avesthagen Limited A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein
IL264336B2 (en) 2009-08-11 2024-02-01 Genentech Inc Production of proteins in cell culture medium without glutamine
WO2011049798A1 (en) 2009-10-20 2011-04-28 Merck Sharp & Dohme Corp. Use of mixed mode chromatography for the capture and purification of basic antibody products
EP2516467A2 (en) 2009-12-23 2012-10-31 Emergent Product Development Seattle, LLC Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
BR112012027282B1 (pt) 2010-04-26 2020-09-29 Novartis Ag Meio de cultura de células aperfeiçoado e processo para a produção de um polipeptídeo recombinante
ES2684921T3 (es) * 2010-05-10 2018-10-05 Intas Pharmaceuticals Limited Formulación líquida de polipéptidos que contienen un dominio Fc de una inmunoglobulina
EP2598167B1 (en) * 2010-07-30 2015-04-01 Arecor Limited Stabilized aqueous antibody compositions
CA2807607A1 (en) 2010-08-20 2012-02-23 Wyeth Llc Cell culture of growth factor-free adapted cells
SG187885A1 (en) 2010-08-31 2013-03-28 Friesland Brands Bv Culture medium for eukaryotic cells
SG10201508401TA (en) 2010-10-11 2015-11-27 Abbvie Bahamas Ltd Processes for purification of proteins
ES2759931T3 (es) 2011-04-20 2020-05-12 Sandoz Ag Formulaciones líquidas farmacéuticas estables de la proteína de fusión TNFR:Fc
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
EP2726081A4 (en) 2011-06-29 2015-04-15 Insite Vision Inc METHOD FOR TREATING RECURRING MIBOMEDE DISEASE AND REDUCING THE FREQUENCY FROM THEIR RECURRENCE
LT2837680T (lt) 2011-07-01 2020-07-10 Amgen Inc. Žinduolių ląstelių kultūra
MX358137B (es) 2011-07-01 2018-08-06 Biogen Idec Inc Composiciones del polipéptido de fusión tnfr: fc exentas de arginina y métodos de uso.
US9781540B2 (en) * 2011-07-07 2017-10-03 Qualcomm Incorporated Application relevance determination based on social context
DK2729482T3 (en) 2011-07-08 2018-05-07 Merck Sharp & Dohme PROCEDURE FOR CLEANING FC-FUSION PROTEIN
WO2013025079A1 (en) 2011-08-17 2013-02-21 Hanwha Chemical Corporation Method for preparing active form of tnfr-fc fusion protein
CN104010654B (zh) * 2011-10-18 2017-10-27 科荣生生物科学公司 金属离子稳定的依那西普制剂
HRP20180182T1 (hr) 2012-09-11 2018-04-20 Coherus Biosciences, Inc. Pravilno presavijeni etanercept visoke čistoće i izvanrednog prinosa

Also Published As

Publication number Publication date
AR088460A1 (es) 2014-06-11
KR20140091705A (ko) 2014-07-22
EP2768535A4 (en) 2015-03-11
US9302002B2 (en) 2016-04-05
IL231826A0 (en) 2014-05-28
MX2014004728A (es) 2015-05-15
HK1200721A1 (en) 2015-08-14
BR112014009073A2 (pt) 2017-05-09
US20190290765A1 (en) 2019-09-26
BR112014009022A2 (pt) 2017-05-02
AU2012326080A1 (en) 2014-04-24
US20190314498A1 (en) 2019-10-17
TW201325608A (zh) 2013-07-01
CA2851642A1 (en) 2013-04-25
EP2768531A4 (en) 2015-03-11
AR088381A1 (es) 2014-05-28
EP2768533A1 (en) 2014-08-27
US20190290767A1 (en) 2019-09-26
SMT201900422T1 (it) 2019-09-09
KR20140091706A (ko) 2014-07-22
KR102163150B1 (ko) 2020-10-08
US10980884B2 (en) 2021-04-20
TW201325610A (zh) 2013-07-01
US20130108632A1 (en) 2013-05-02
EP2768525B1 (en) 2019-06-19
US10376588B2 (en) 2019-08-13
PT2768525T (pt) 2019-07-17
EA026410B1 (ru) 2017-04-28
EP2768525A1 (en) 2014-08-27
HK1200719A1 (en) 2015-08-14
IN2014CN02591A (enExample) 2015-06-26
CY1121843T1 (el) 2020-07-31
JP6104922B2 (ja) 2017-03-29
CN103998060A (zh) 2014-08-20
EA201490803A1 (ru) 2014-09-30
EA025267B1 (ru) 2016-12-30
JP2014530254A (ja) 2014-11-17
JP6220788B2 (ja) 2017-10-25
EA201490815A1 (ru) 2014-09-30
JP6110393B2 (ja) 2017-04-05
SG11201401562RA (en) 2014-09-26
WO2013059407A1 (en) 2013-04-25
BR112014009146A8 (pt) 2017-06-20
EP2768525A4 (en) 2015-07-15
CN104011073B (zh) 2017-08-25
SG11201401517VA (en) 2014-09-26
EP2768532A4 (en) 2015-03-11
IL231824A0 (en) 2014-05-28
HK1200851A1 (en) 2015-08-14
WO2013059406A1 (en) 2013-04-25
BR112014009031A2 (pt) 2017-05-09
JP2014530863A (ja) 2014-11-20
JP6220789B2 (ja) 2017-10-25
SG11201401519RA (en) 2014-07-30
MX2014004725A (es) 2015-02-05
TWI644681B (zh) 2018-12-21
CN103998060B (zh) 2016-12-21
AU2012326084A1 (en) 2014-04-17
AU2012326082B2 (en) 2016-12-15
KR20140079491A (ko) 2014-06-26
SG11201401567YA (en) 2014-07-30
HK1200718A1 (en) 2015-08-14
US20130101584A1 (en) 2013-04-25
US20130101640A1 (en) 2013-04-25
IL231829A0 (en) 2014-05-28
US20180125982A1 (en) 2018-05-10
CN104010654B (zh) 2017-10-27
KR20200008021A (ko) 2020-01-22
EA201490817A1 (ru) 2014-09-30
IL231827A0 (en) 2014-05-28
US20190328875A1 (en) 2019-10-31
WO2013059405A1 (en) 2013-04-25
HRP20191215T1 (hr) 2019-10-04
TWI619504B (zh) 2018-04-01
SG11201401576WA (en) 2014-10-30
TW201325609A (zh) 2013-07-01
LT2768525T (lt) 2019-09-25
IN2014CN02592A (enExample) 2015-09-04
MX2014004734A (es) 2015-05-15
AR088380A1 (es) 2014-05-28
US10293049B2 (en) 2019-05-21
US9393305B2 (en) 2016-07-19
CA2851639C (en) 2020-12-29
US9770510B2 (en) 2017-09-26
JP2014530862A (ja) 2014-11-20
TW201325611A (zh) 2013-07-01
EP2768533A4 (en) 2015-03-11
AR088382A1 (es) 2014-05-28
US20160199489A1 (en) 2016-07-14
US10980885B2 (en) 2021-04-20
CA2851651A1 (en) 2013-04-25
AU2012326171B2 (en) 2017-03-09
EA201490802A1 (ru) 2014-08-29
MX2014004733A (es) 2015-05-15
TW201325606A (zh) 2013-07-01
SI2768525T1 (sl) 2019-10-30
US20190298837A1 (en) 2019-10-03
AU2012326082A1 (en) 2014-04-24
KR102068462B1 (ko) 2020-01-22
US20190290766A1 (en) 2019-09-26
EP2768854A4 (en) 2015-03-11
KR20140097184A (ko) 2014-08-06
JP6113176B2 (ja) 2017-04-12
US20190290768A1 (en) 2019-09-26
US20180193463A1 (en) 2018-07-12
MX2014004732A (es) 2015-05-15
MX2014004726A (es) 2015-05-15
SG11201401563SA (en) 2014-09-26
JP2014530864A (ja) 2014-11-20
BR112014009131A2 (pt) 2017-06-13
PL2768525T3 (pl) 2019-10-31
US10213508B2 (en) 2019-02-26
US10987405B2 (en) 2021-04-27
HK1200722A1 (en) 2015-08-14
WO2013059410A1 (en) 2013-04-25
AU2012326171A1 (en) 2014-04-24
CN103998061A (zh) 2014-08-20
EA027325B1 (ru) 2017-07-31
CA2851635A1 (en) 2013-04-25
EA025663B1 (ru) 2017-01-30
JP2014530256A (ja) 2014-11-17
BR112014009087A2 (pt) 2017-04-18
US9801942B2 (en) 2017-10-31
EP2768535A1 (en) 2014-08-27
MX2019009176A (es) 2019-10-07
US20190314500A1 (en) 2019-10-17
EA201490801A1 (ru) 2014-09-30
CN104010654A (zh) 2014-08-27
CA2851628A1 (en) 2013-04-25
CN104010658A (zh) 2014-08-27
EP2768532A1 (en) 2014-08-27
US10772963B2 (en) 2020-09-15
CA2851639A1 (en) 2013-04-25
AU2012326168B2 (en) 2016-12-15
AU2012326168A1 (en) 2014-04-24
AU2012326080B2 (en) 2017-02-16
US20190184017A1 (en) 2019-06-20
IN2014CN02527A (enExample) 2015-06-26
CN104010657A (zh) 2014-08-27
US11135267B2 (en) 2021-10-05
AU2012326170B2 (en) 2016-12-22
RS59179B1 (sr) 2019-10-31
US9943601B2 (en) 2018-04-17
US10888619B2 (en) 2021-01-12
DK2768525T3 (da) 2019-07-22
HUE045624T2 (hu) 2020-01-28
US20200405865A1 (en) 2020-12-31
KR20140083037A (ko) 2014-07-03
US20130108633A1 (en) 2013-05-02
JP6199298B2 (ja) 2017-09-20
IL231828A0 (en) 2014-05-28
US20180028668A1 (en) 2018-02-01
EA201490804A1 (ru) 2014-09-30
US11129876B2 (en) 2021-09-28
TW201325607A (zh) 2013-07-01
BR112014009131A8 (pt) 2017-06-20
WO2013059408A1 (en) 2013-04-25
US20160317667A1 (en) 2016-11-03
CN104011073A (zh) 2014-08-27
EA028520B1 (ru) 2017-11-30
AR088379A1 (es) 2014-05-28
AU2012326084B2 (en) 2016-12-15
KR20140091707A (ko) 2014-07-22
AR088383A1 (es) 2014-05-28
AU2012326170A1 (en) 2014-04-24
CA2851646A1 (en) 2013-04-25
BR112014009146A2 (pt) 2017-06-13
TWI595883B (zh) 2017-08-21
ES2734070T3 (es) 2019-12-04
US20190314499A1 (en) 2019-10-17
US20190216930A1 (en) 2019-07-18
JP2014530255A (ja) 2014-11-17
EP2768531A1 (en) 2014-08-27
HK1200720A1 (en) 2015-08-14
WO2013059412A1 (en) 2013-04-25
MX367054B (es) 2019-08-02
EP2768854A1 (en) 2014-08-27

Similar Documents

Publication Publication Date Title
IL231825A0 (en) Formulations of ethenecept stabilized with metal ions
ZA201400692B (en) Stabilized subtilisin composition
IL227758A0 (en) Copper-nickel-zinc-manganese alloy
ZA201402914B (en) Hard metal composition
ZA201308893B (en) Low water metal ion dentifrice
IL239125A0 (en) Preparations containing a stable metal ion
ZA201303555B (en) Metal ion nanoclusters
IL230217B (en) New mutations ecd–r17–il
EP2663671A2 (en) Metal treatment
EP2691106A4 (en) ANTIVIRAL COMPOSITION
IL214102A0 (en) Wide area neutralizer
GB201103569D0 (en) Mutants
GB201108912D0 (en) Composition
GB201103964D0 (en) Composition
EP2711011A4 (en) COMPOSITION CONTAINING PANAXADIOL
ZA201306909B (en) Antiviral composition
GB201113058D0 (en) Metal conduit assemblies
GB201106733D0 (en) Metal treatment
GB201100605D0 (en) Metal treatment
PL395179A1 (pl) Specyficzna sekwencyjnie rybonukleaza H
PH32011001049S1 (en) Metal plate
PH32011001046S1 (en) Metal plate
PH32011001048S1 (en) Metal plate
PH32011001047S1 (en) Metal plate
EP2908969A4 (en) METHOD OF INJECTING METAL ALLOYS